UK-based biopharma firm Izana Bioscience said it was testing its antibody therapy namilumab for the therapy of patients with quickly worsening COVID-19 at the Humanitas Analysis Hospitals in Bergamo and Milan in Italy.
Namilumab is a monoclonal antibody remedy at the moment in late-stage clinical growth for the treatment of rheumatoid arthritis and ankylosing spondylitis.
It targets a white cell growth factor called GM-CSF, which has been present in greater levels in COVID-19 sufferers, based on recent data from China, Izana Bioscience mentioned. Early intervention may, due to this fact, be beneficial for sufferers with COVID-19, the illness caused by the novel coronavirus.
Chief executive officer and co-founder Someit Sidhu mentioned: “The role of GM-CSF in immune-mediated illnesses is backed by a robust body of evidence and our growing understanding of COVID-19.
“Proof suggests that anti-GM-CSF therapy has the potential to alter the way sufferers’ immune systems respond to the virus, and therefore to cut back dangerous irritation and support recovery.”
The compassionate use program is headed by Professor Carlo Selmi, Izana mentioned, while analysis services are being provided by Ergomed. Japan’s Takeda has a strategic equity holding in Izana.